Olorofim in Early Coccidioidal Meningitis

Phase 2, Open-label Evaluation of Olorofim in Early Coccidioidal Meningitis

This research study is being conducted to learn more about the use of olorofim in Coccidioidal (Cocci) meningitis, a rare but serious fungal infection that affects the brain and spinal cord. The study is exploratory, meaning that early information is being gathered to better understand the effectiveness of olorofim in coccidioidal meningitis in its early stages. The study plans to enroll approximately 10 to 12 participants who have been recently diagnosed-within the last 4 to 8 weeks-and who do not have a ventriculoperitoneal (VP) shunt, a medical device sometimes used to relieve pressure in the brain. Participants will be followed for approximately 6 months, during which health information will be collected to evaluate disease progression and response to treatment. Participants may have the opportunity to enroll in the olorofim Managed Access Program to continue treatment after completion of the study period.

Study Overview

• Status: Not yet recruiting
• Conditions: Coccidioidal Meningitis
• Intervention / Treatment: Drug: olorofim

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Jose Elizondo; Phone Number: 5206210316; Email: joselizondo5@arizona.edu

Study Locations

• United States
  • Arizona
    • Tucson, Arizona, United States, 85719
      • Banner University Medical Center
      • Contact: Jose Elizondo; Phone Number: 5206210316; Email: joselizondo5@arizona.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male and female patients aged ≥ 18 years and weighing ≥ 40 kg, able to understand and consent in English, who have been fully informed and:

   a) who have given voluntary written informed consent, or whose legally authorized representative(s) has been fully informed and has given voluntary written informed consent if applicable, and in compliance with local regulations OR

2. b) who have given oral informed consent witnessed in writing by an independent person and in compliance with local regulations for patients who are unable to write and/or read but who fully understand the oral information given by the Investigator (or nominated representative).
3. Ongoing coccidioidomycotic meningitis diagnosed within 8 weeks prior to enrolment.
4. Ongoing symptoms due to coccidioidomycosis are such that the risk-benefit of treatment with an investigational agent with a hepatic signal requiring careful monitoring is judged favorable based on meeting criteria

5. Female patients must be non-lactating and at no risk of pregnancy for one of the following reasons:

   • Postmenopausal for at least 1 year;
   • Post-hysterectomy and/or post-bilateral oophorectomy;

   • Of childbearing potential, with a negative urine or serum human chorionic gonadotropin pregnancy test at the screening visit and must be using one of listed below highly effective method of birth control throughout the course of the study period and up to and including 30 days after stopping study drug

     • Established use of oral, injected, transdermal, intravaginal, or implanted hormonal methods of contraception associated with inhibition of ovulation
     • Placement of an intrauterine device or intrauterine hormone-releasing system
     • Male sterilization
     • Bilateral tubal occlusion
     • Sexual abstinence (reliable sexual abstinence is acceptable but periodic abstinence [e.g., calendar, ovulation, symptom-thermal, or post-ovulation methods] and withdrawal are not acceptable).
6. Male patients with female partners of childbearing potential must either totally abstain from sexual intercourse or use a highly effective means of contraception throughout study participation and agree to continue its use for 30 days after stopping study drug and may not donate semen during this time.

Exclusion Criteria:

1. Patients who are unconscious.
2. Patients who are pregnant or breastfeeding.
3. Known history of allergy, hypersensitivity, or any serious reaction to any component of the olorofim.
4. Patients with or planned placement of indwelling CNS hardware (e.g. reservoirs, shunts, ventriculostomies, or external drainage tubes).
5. Patients with a second fungal infection requiring systemic antifungal treatment or prophylaxis, other than Pneumocystis jirovecii infections and cutaneous fungal infections treated topically.
6. Patients with microbiological findings (e.g., bacteriological, virological) or other potential conditions that are temporally related and suggest a different than study indication etiology.
7. HIV infection but not currently receiving antiretroviral therapy. In cases where HIV infection is first diagnosed at the same time as the invasive fungal infection, if antiretroviral therapy is commenced at the time of enrollment, then such patients are eligible for enrolment
8. Any known or suspected medical condition or social circumstance of the patient that may jeopardize adherence to the protocol requirements or impede the accurate measurement of efficacy.
9. Patients with a concomitant medical condition that, in the opinion of the Investigator, may be an unacceptable additional risk to the patient should he/she participate in the study.
10. Patients who have received prior treatment with olorofim/F901318.
11. Treatment with any investigational drug within the 30 days prior to the first administration of study drug except for unblinded protocols (eg, open-label oncological regimen variations or biologic studies). Prior to enrolling patients who are on other open-label studies, it is the site's responsibility to ensure that the study criteria for that study allow for enrollment into this study.
12. Patients receiving treatment limited to supportive care due to predicted short survival time.

13. Patients with a baseline prolongation of QT using Fridericia's Correction Formula (QTcF) ≥ 500 msec, or at high risk for QT/QTc prolongation, eg,

    1. A family history of long QT syndrome
    2. Other known pro-arrhythmic conditions
    3. Risk factors for Torsade de Pointes (e.g., uncompensated heart failure, abnormal plasma potassium or magnesium levels that cannot be corrected, an unstable cardiac condition during the last 30 days).

14. Evidence of hepatic dysfunction with any of the following abnormal laboratory parameters at screening:

    1. Total bilirubin ≥ 2 × upper limit of the normal range (ULN), OR
    2. Alanine transaminase (ALT) or aspartate transaminase (AST) ≥ 3 × ULN, OR
    3. Patients with known cirrhosis or chronic hepatic failure (regardless of ALT/AST/total bilirubin).

    Liver transplant recipients may be enrolled if their laboratory parameters do not meet the laboratory exclusions given above.

15. Prohibited concomitant medications. Concomitant administration of inhibitors of human dihydro-orotate dehydrogenase (DHODH), teriflunomide, leflunomide, and systemic use of cannabis/cannabinoid preparations, including tetrahydrocannabinol (THC) and cannabidiol (CBD) are prohibited. There are currently no other absolutely prohibited concomitant medications for olorofim but there are medications with potentially significant drug-drug interactions (DDIs) with olorofim or SOC and the management of potential interactions should be considered before study enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: olorofim; Participants will receive treatment with olorofim	Drug: olorofim; Single group study - all participants will receive olorofim treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety: Number of participants with ≥1 treatment-emergent adverse event	Counts and proportions of participants experiencing at least one adverse event after initiation of olorofim, regardless of causality. Adverse events will be coded and graded according to CTCAE v5.0.	First dose through end of treatment and 4-week follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy: Investigator-assessed clinical response over 24 weeks	Proportion of participants with improvement or resolution of coccidioidal meningitis-related clinical signs and symptoms compared with baseline, as assessed by the investigator at protocol-specified visits.	Baseline through Week 24 (End of Treatment)
Efficacy: Change from baseline in Coccidioides serum complement fixation titers	Change in serum complement fixation titers from baseline, measured at scheduled study visits, as an indicator of mycological and disease response.	Baseline through Week 24
Efficacy: Radiological response assessed by imaging	Proportion of participants with stable or improved radiological findings related to coccidioidal meningitis on clinically indicated imaging studies compared with baseline.	Baseline through Week 24
Efficacy: Investigator-assessed overall treatment response	Proportion of participants with overall response based on integration of clinical status, radiological findings (if available), and mycological/serologic data, as assessed by the investigator using protocol-defined criteria.	Baseline through Week 24
Efficacy: All-cause mortality	Proportion of participants who die from any cause during treatment or follow-up.	Baseline through Week 24 and 4-week follow-up
Patient-reported Outcome: Change from baseline in Modified Zubrod Performance Score	Change from baseline in MZ-PS, a measure of functional performance status.	Baseline through Week 24
Patient-reported Outcome: Change from baseline in Valley Fever Patient-Reported Outcomes (VF-PRO) score	Change from baseline in VF-PRO questionnaire scores assessing symptom burden and quality of life related to coccidioidomycosis.	Baseline through Week 24
Patient-reported Outcome: Change from baseline in Clinical Global Impression-Severity (CGI-S) and Patient Global Impression-Severity (PGI-S)	Change from baseline in investigator-rated (CGI-S) and patient-reported (PGI-S) disease severity scores. (separate scales but reported similarly)	Baseline through Week 24
ECG Sub-Study: Change from baseline in QTcF interval	Change in QT interval corrected using Fridericia's formula (QTcF), measured using continuous Holter ECG monitoring and time-matched with plasma olorofim concentrations in a subset of participants.	Day 10-21 (single study day)

Collaborators and Investigators

• Sponsor: Fariba Donovan
• Collaborators: F2G Biotech GmbH
• Investigators: Principal Investigator: Fariba Donovan, MD, PhD, University of Arizona

Study record dates

Study Major Dates

• Study Start (Estimated): March 15, 2026
• Primary Completion (Estimated): March 15, 2027
• Study Completion (Estimated): June 15, 2027

Study Registration Dates

• First Submitted: January 23, 2026
• First Submitted That Met QC Criteria: January 26, 2026
• First Posted (Actual): February 4, 2026

Study Record Updates

• Last Update Posted (Actual): February 4, 2026
• Last Update Submitted That Met QC Criteria: January 26, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: coccidioidomycosis
• Additional Relevant MeSH Terms: Neuroinflammatory Diseases; Central Nervous System Diseases; Nervous System Diseases; Infections; Bacterial Infections and Mycoses; Central Nervous System Infections; Meningitis, Fungal; Central Nervous System Fungal Infections; Mycoses; Meningitis; Coccidioidomycosis; Coccidioidal Meningitis; olorofim
• Other Study ID Numbers: Study 00006853

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified individual participant data (IPD), including the analyzable dataset and associated metadata, will be shared with the study collaborator, F2G Ltd., for purposes of regulatory support, safety evaluation, and further analysis related to olorofim. Data shared will not include direct identifiers and will be coded prior to transfer.
• IPD Sharing Access Criteria: Access to the de-identified IPD will be limited to F2G Ltd. and authorized third-party vendors acting on behalf of the collaborator, under data use agreements that specify permitted uses and prohibit re-identification. Data will not be made publicly available. Study results may be disseminated through scientific publications and presentations.
• IPD Sharing Supporting Information Type: CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No